title: Dramatic response to temozolomide, irinotecan, and bevacizumab for recurrent medulloblastoma with widespread osseous metastases.
abstract: There is little evidence to guide the choice of chemotherapeutic agents for osseous metastases in medulloblastoma. Recently, triple therapy with temozolomide, irinotecan, and bevacizumab has been reported to have efficacy in recurrent medulloblastoma, and this regimen alone and in combination with other agents has been tested in several early-phase clinical trials. Here we report a 20-year-old woman with multiply-relapsed medulloblastoma with numerous osseous metastases 8 years after original diagnosis who responded dramatically to temozolomide, irinotecan, and bevacizumab therapy. This case highlights the potential for this regimen in treating osseous metastases in medulloblastoma.
authors.affiliation: Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Phillip A
authors.initials: PA
authors.lastname: Bonney
authors.affiliation: Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Joshua A
authors.initials: JA
authors.lastname: Santucci
authors.affiliation: Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Adrian J
authors.initials: AJ
authors.lastname: Maurer
authors.affiliation: Department of Neurosurgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA; Oklahoma Comprehensive Brain Tumor Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Sughrue
authors.affiliation: Department of Pediatrics, Hematology-Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
authors.forename: Rene Y
authors.initials: RY
authors.lastname: McNall-Knapp
authors.affiliation: Department of Neurology, University of Oklahoma Health Sciences Center, Williams Pavilion, 920 Stanton L. Young Boulevard, Suite 2040, Oklahoma City, OK 73104, USA; Oklahoma Comprehensive Brain Tumor Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: james-battiste@ouhsc.edu.
authors.forename: James D
authors.initials: JD
authors.lastname: Battiste
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008527:Medulloblastoma / Q000188:drug therapy* / Q000556:secondary; D000077204:Temozolomide; D055815:Young Adult
chemical_list: D000068258:Bevacizumab; D000077146:Irinotecan; D003606:Dacarbazine; D002166:Camptothecin; D000077204:Temozolomide
keywords: Bevacizumab; Irinotecan; Medulloblastoma; Osseous metastasis; Recurrent; Temozolomide